Indian Patient Experience on Adalimumab

Speciality: Rheumatology


Speaker:

Dr. Sumeet Agrawal - Moderator | Head of Rheumatology and Clinical Immunology,

Dr. Himanshu Aggarwal - Speaker | Consultant Rheumatologist

Dr. Puneet Srivastava - Speaker | Senior Consultant Rheumatologist

Dr. Shubha Bhalla - Speaker | Consultant Rheumatologist

Description:

A warm welcome to all the medical professionals in this interesting session on Indian Patient Experience on Adalimumab
Adalimumab, a widely used biologic for treating various autoimmune conditions, has garnered positive feedback from Indian patients for its efficacy in managing diseases such as rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Patients report significant improvements in symptom relief, including reduced pain, swelling, and skin lesions, leading to enhanced quality of life. This biologic’s ability to provide rapid and sustained symptom control has been particularly appreciated, allowing patients to regain mobility and participate more actively in daily activities.
However, the high cost of adalimumab remains a significant barrier for many Indian patients, limiting its accessibility despite its proven benefits. To address this issue, the introduction of biosimilars has provided a more affordable alternative, increasing the number of patients who can benefit from this treatment. Patients using biosimilar versions have reported similar therapeutic outcomes, making these options a valuable addition to the treatment landscape in India.
Therefore, get an overall knowledge of indian patient experience on adalimumab
 

See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Financial hardship for cancer survivors due to high-cost immunotherapies, especially for blood cancer patients

2.

In-person and Virtual Palliative Care Are Both Beneficial for Advanced Lung Cancer Patients.

3.

Kidney cancer: Understanding what a renal cell carcinoma diagnosis means

4.

AI tool automates liver tumor detection and monitoring

5.

FDA Bans Red Dye No. 3 From Foods, Ingested Drugs


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot